SCHEMBL6480103

SCHEMBL6480103

CCOC(=O)c1cccc(N/N=C(\C)c2cc[nH]n2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.53
ALDH1A1 P00352 3/20 0.53
TSHR P16473 1/20 0.53
SMN1; SMN2 Q16637 8/20 0.49
RAB9A P51151 7/20 0.49
NPC1 O15118 6/20 0.49
KDM4E B2RXH2 1/20 0.49
HPGD P15428 2/20 0.47
TP53 P04637 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
POLB P06746 1/20 0.46
PKM P14618 1/20 0.46
MAPT P10636 4/20 0.45
MEN1 O00255 2/20 0.45
ABCB1 P08183 1/20 0.45
HTT P42858 1/20 0.45
ABCG2 Q9UNQ0 1/20 0.45
CDC25B P30305 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5755860 1.00 KMT2A (0.53) KMT2AALDH1A1TSHRSMN1; SMN2RAB9A
SCHEMBL5751505 0.75 MAPT (0.48) KMT2AALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL5754707 0.75 MAPT (0.48) KMT2AALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL921752 0.74 KMT2A (0.53) KMT2AALDH1A1TSHRSMN1; SMN2RAB9A
SCHEMBL7808621 0.71 SMN1; SMN2 (0.70) KMT2AALDH1A1TSHRSMN1; SMN2RAB9A
SCHEMBL22062005 0.71 KMT2A (0.55) KMT2AALDH1A1TSHRSMN1; SMN2RAB9A
SCHEMBL7672431 0.71 ALDH1A1 (0.55) KMT2AALDH1A1TSHRSMN1; SMN2RAB9A
SCHEMBL584215 0.71 KMT2A (0.65) KMT2AALDH1A1TSHRSMN1; SMN2RAB9A
SCHEMBL561497 0.70 CYP1A2 (0.56) KMT2AALDH1A1TSHRSMN1; SMN2RAB9A
SCHEMBL922022 0.70 SMN1; SMN2 (0.53) KMT2AALDH1A1TSHRSMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032869-A1 Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032869-A1 Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K9, MAP3K20, MAP3K19 KMT2A 1158/4885ALDH1A1 2469/4885TSHR 2449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.